Preview

Анналы хирургической гепатологии

Расширенный поиск

Гепатоцеллюлярный рак у детей - основные отличия от взрослых пациентов

https://doi.org/10.16931/1995-5464.2020485-94

Полный текст:

Аннотация

Цель: сравнить особенности гепатоцеллюлярного рака у детей и взрослых, а также оценить возможность экстраполяции опыта лечения взрослых пациентов на педиатрическую практику.
Материал и методы. Проведен анализ литературы, посвященной изучению и лечению гепатоцеллюлярного рака у детей и взрослых. Отдельное внимание уделено сравнению патоморфологических и молекулярно-генетических особенностей болезни и подходов к медикаментозному и хирургическому лечению, в частности иммунотерапии и трансплантации печени.
Результаты. Для гепатоцеллюлярного рака у детей характерно превалирование фиброламеллярного гистологического подтипа, наличие характерных молекулярно-генетических маркеров, большие размеры первичной опухоли. У детей целесообразно применять методы лечения, заимствованные у взрослых, – таргетную и иммунотерапию. Подходы к хирургическому лечению, в частности показания к трансплантации печени, у детей должны отличаться.
Заключение. Дальнейший перенос опыта лечения взрослых пациентов на детскую популяцию позволит улучшить результаты лечения детей с гепатоцеллюлярным раком. Работа в рамках международных исследовательских групп необходима для оптимизации лечения детей с гепатоцеллюлярным раком.

Об авторах

Д. Г. Ахаладзе
ФГБУ "НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачёва" Минздрава России
Россия

Ахаладзе Дмитрий Гурамович – канд. мед. наук, руководитель группы торакоабдоминальной хирургии

117997, Москва, ул. Саморы Машела, д. 1, Тел.: 8-905-587-89-92



Г. С. Рабаев
ФГБУ "НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачёва" Минздрава России
Россия

Рабаев Гавриил Савельевич – врач – детский хирург отделения онкологии и детской хирургии

117997, Москва, ул. Саморы Машела, д. 1



Список литературы

1. Stuver S., Trichopoulos D. Cancer of the liver and biliary tract. In: Adami H.O., Hunter D., Trichopoulos D., editors. Textbook of Cancer Epidemiology. 2nd ed. NewYork: Oxford University Press; 2008. P. 308–332.

2. Tang A., Hallouch O., Chernyak V., Kamaya A., Sirlin C.B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (NY). 2018; 43 (1): 13–25. https://doi.org/10.1007/s00261-017-1209-1.

3. World Health Organization, I.A.f.R.o.C. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: https://www.iarc.fr/news-events/latest-worldcancer-statistics-globocan-2012-estimated-cancer-incidencemortality-and-prevalence-worldwide-in-2012/ (дата обращения: 06.05.2020).

4. SEER Cancer Statistics Factsheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. 2014. [Last accessed on 2017 Apr]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html (дата обращения: 06.05.2020).

5. Ghouri Y.A., Mian I., Rowe J.H. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J. Carcinog. 2017; 16: 1. https://doi.org/10.4103/jcar.JCar_9_16.

6. Czauderna P., Mackinlay G., Perilongo G., Brown J., Shafford E., Aronson D., Pritchard J., Chapchap P., Keeling J., Plaschkes J., Otte J.B. Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J. Clin. Oncol. 2002; 20 (12): 2798–2804. https://doi.org/10.1200/JCO.2002.06.102.

7. McGlynn K.A., London W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin. Liver Dis. 2011; 15 (2): 223–243. vii-x. https://doi.org/10.1016/j.cld.2011.03.006.

8. Czauderna P. Adult type vs. Childhood hepatocellular carcinoma – are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med. Pediatr. Oncol. 2002; 39 (5): 519–523. https://doi.org/10.1002/mpo.10178.

9. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365 (12): 1118–1127. https://doi.org/10.1056/NEJMra1001683.

10. Kelly D., Sharif K., Brown R.M., Morland B. Hepatocellular carcinoma in children. Clin. Liver Dis. 2015; 19 (2): 433–447. https://doi.org/10.1016/j.cld.2015.01.010.

11. Lau C.S., Mahendraraj K., Chamberlain R.S. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the Surveillance, Epidemiology, and End Result (SEER) database (1973–2011). HPB Surg. 2015; 2015: 670728. https://doi.org/10.1155/2015/670728.

12. Litten J.B., Tomlinson G.E. Liver tumors in children. Oncologist. 2008; 13 (7): 812–820. https://doi.org/10.1634/theoncologist.2008-0011.

13. Otte J.B. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat. Rev. 2010; 36 (4): 360–371. https://doi.org/10.1016/j.ctrv.2010.02.013.

14. Darbari A., Sabin K.M., Shapiro C.N., Schwarz K.B. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology (Baltimore, Md). 2003; 38 (3): 560–566. https://doi.org/10.1053/jhep.2003.50375.

15. Buendia M.A. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med. Pediatr. Oncol. 2002; 39 (5): 530–535. https://doi.org/10.1002/mpo.10180.

16. Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Qu W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003; 97 (8): 2006–2012. https://doi.org/10.1002/cncr.11292.

17. Aronson D.C., Meyers R.L. Malignant tumors of the liver in children. Semin. Pediatr. Surg. 2016; 25 (5): 265–275. https://doi.org/10.1053/j.sempedsurg.2016.09.002.

18. Weeda V.B., Aronson D.C., Verheij J., Lamers W.H. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. Pediat. Blood Cancer. 2019; 66 (2): e27475. https://doi.org/10.1002/pbc.27475.

19. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv. Anat. Pathol. 2007; 14 (3): 217–223. https://doi.org/10.1097/PAP.0b013e3180504913.

20. Prokurat A., Kluge P., Kosciesza A., Perek D., Kappeler A., Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med. Pediatr. Oncol. 2002; 39 (5): 510–518. https://doi.org/10.1002/mpo.10177.

21. Eichenmüller M., Trippel F., Kreuder M., Beck A., Schwarzmayr T., Häberle B., Cairo S., Leuschner I., von Schweinitz D., Strom T.M., Kappler R. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 2014; 61 (6): 1312–1320. https://doi.org/10.1016/j.jhep.2014.08.009.

22. López-Terrada D., Alaggio R., de Dávila M.T., Czauderna P., Hiyama E., Katzenstein H., Leuschner I., Malogolowkin M., Meyers R., Ranganathan S., Tanaka Y., Tomlinson G., Fabrè M., Zimmermann A., Finegold M.J. Children's Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod. Pathol. 2014; 27 (3): 472–491. https://doi.org/10.1038/modpathol.2013.80.

23. Jain S., Singhal S., Lee P., Xu R. Molecular genetics of hepatocellular neoplasia. Am. J. Transl. Res. 2010; 2 (1): 105–118.

24. Cieply B., Zeng G., Proverbs-Singh T., Geller D., Monga S. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009; 49 (3): 821–831. https://doi.org/10.1002/hep.22695.

25. Yamaoka H., Ohtsu K., Sueda T., Yokoyama T., Hiyama E. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol. Rep. 2006; 15 (3): 551–556.

26. Vilarinho S., Erson-Omay E.Z., Harmanci A.S., Morotti R., Carrion-Grant G., Baranoski J., Knisely A.S., Ekong U., Emre S., Yasuno K., Bilguvar K., Günel M. Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. J. Hepatol. 2014; 61 (5): 1178–1183. https://doi.org/10.1016/j.jhep.2014.07.003.

27. Chu J.S., Ge F.J., Zhang B., Wang Y., Silvestris N., Liu L.J., Zhao C.H., Lin L., Brunetti A.E., Fu Y.L., Wang J., Paradiso A., Xu J.M. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2013; 32 (1): 16. https://doi.org/10.1186/1756-9966-32-16.

28. Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59 (2): 307–310.

29. Chen J., Wang Q., Fu X., Huang X.H., Chen X.L., Cao L.Q., Chen L.Z., Tan H.X., Li W., Bi J., Zhang L.J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 2009; 39 (2): 177–186. https://doi.org/10.1111/j.1872-034X.2008.00449.x.

30. Soini T., Haveri H., Elo J., Kauppinen M., Kyrönlahti A., Salo M.K., Lohi J., Andersson L.C., Wilson D.B., Heikinheimo M. Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. J. Pediatr. Gastroenterol. 2012; 54 (1): 101–108. https://doi.org/10.1097/MPG.0b013e31822d52cf.

31. Cornella H., Sayols S., Zhang Z., Hao K., Cabellos L., Hoshida Y. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; 148 (4): 806–818. e10. https://doi.org/10.1053/j.gastro.2014.12.028.

32. Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I., Gleason C.E., Murphy J.M., Rosenberg B.R., Teegan L., Takacs C.N., Botero S., Belote R., Germer S., Emde A.K., Vacic V., Bhanot U., LaQuaglia M.P., Simon S.M. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343 (6174): 1010–1014. https://doi.org/10.1126/science.1249484.

33. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., Miller M.L., Rekhtman N., Moreira A.L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E.B., Merghoub T., Wolchok J.D., Schumacher T.N., Chan T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348 (6230): 124–128. https://doi.org/10.1126/science.aaa1348.

34. Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 2019; 30 (1): 44–56. https://doi.org/10.1093/annonc/mdy495.

35. Ang C., Klempner S.J., Ali S.M., Madison R., Ross J.S., Severson E.A., Fabrizio D., Goodman A., Kurzrock R., Suh J., Millis S.Z. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019; 10 (40): 4018–4025. https://doi.org/10.18632/oncotarget.26998.

36. Shrestha R., Prithviraj P., Anaka M., Bridle K.R., Crawford D., Dhungel B., Steel J.C., Jayachandran A. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front. Oncol. 2018; 8: 269. https://doi.org/10.3389/fonc.2018.00269.

37. Murawski M., Weeda V.B., Maibach R., Morland B., Roebuck D.J., Zimmerman A., Casanova M., Perilongo G., Laithier V., Kebudi R., Scopinaro M.J., Shun A., Brichard B., de Camargo B., Childs M., Aronson D.C., Czauderna P. Hepatocellular carcinoma in children: does modified platinumand doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J. Clin. Oncol. 2016; 34 (10): 1050–1056. https://doi.org/10.1200/JCO.2014.60.2250.

38. Schmid I., Albert M.H., Haberle B. HB99-Hepatozellulare Karzinome: Behandlungsergebnisse und neueKonzepte. Monatsschr. Kinderheilkd. 2008; 156: 412.

39. Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Liu-Mares W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J. Clin. Oncol. 2002; 20 (12): 2789–2797. https://doi.org/10.1200/JCO.2002.06.155.

40. Paediatric Hepatic International Tumour Trial (PHITT) https://clinicaltrials.gov/ct2/show/NCT03017326 (дата обращения: 06.05.2020).

41. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359 (4): 378–390. https://doi.org/10.1056/NEJMoa0708857.

42. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., Leung T., Gansukh B., Saltz L.B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304 (19): 2154–2160. https://doi.org/10.1001/jama.2010.1672.

43. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.

44. Ganten T.M., Stauber R.E., Schott E., Malfertheiner P., Buder R., Galle P.R., Göhler T., Walther M., Koschny R., Gerken G. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin. Cancer Res. 2017; 23 (19): 5720–5728. https://doi.org/10.1158/1078-0432.CCR-16-0919.

45. Schmid I., Häberle B., Albert M.H., Corbacioglu S., Fröhlich B., Graf N., Kammer B., Kontny U., Leuschner I., ScheelWalter H.G., Scheurlen W., Werner S., Wiesel T., von Schweinitz D. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr. Blood Cancer. 2012; 58 (4): 539–544. https://doi.org/10.1002/pbc.23295.

46. Schmid I., von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J. Hepatocell. Carcinoma. 2017; 4: 15–21. https://doi.org/10.2147/JHC.S94008.

47. Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Piscaglia F., Baron A., Park J.W., Han G., Jassem J., Blanc J.F., Vogel A., Komov D., Evans J., Lopez C., Dutcus C., Guo M., Saito K., Kraljevic S., Tamai T., Ren M., Cheng A.L. Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 trial. Lancet. 2018; 391 (10126): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

48. Bruix J., Qin S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., Gerolami R., Masi G., Ross P.J., Song T., Bronowicki J.P., OllivierHourmand I., Kudo M., Cheng A.L., Llovet J.M., Finn R.S., LeBerre M.A., Baumhauer A., Meinhardt G., Han G. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

49. Abou-Alfa G.K., Meyer T., Cheng A.L., El-Khoueiry A.B., Rimassa L., Ryoo B.Y., Cicin I., Merle P., Chen Y., Park J.W., Blanc J.F., Bolondi L., Klümpen H.J., Chan S.L., Zagonel V., Pressiani T., Ryu M.H., Venook A.P., Hessel C., BorgmanHagey A.E., Schwab G., Kelley R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018; 379 (1): 54–63. https://doi.org/10.1056/NEJMoa1717002.

50. Zhu A.X., Park J.O., Ryoo B.Y., Yen C.J., Poon R., Pastorelli D., Blanc J.F., Chung H.C., Baron A.D., Pfiffer T.E., Okusaka T., Kubackova K., Trojan J., Sastre J., Chau I., Chang S.C., Abada P.B., Yang L., Schwartz J.D., Kudo M. REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16 (7): 859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.

51. Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J. Gastroenterol. 2019; 25 (7): 789–807. https://doi.org/10.3748/wjg.v25.i7.789.

52. Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology. 2017; 92 (Suppl 1): 50–62. https://doi.org/10.1159/000451016.

53. Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19 (7): 940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.

54. Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT04134559 (дата обращения: 06.05.2020).

55. Zhou F., Shang W., Yu X., Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med. Res. Rev. 2018; 38 (2): 741–767. https://doi.org/10.1002/med.21455.

56. El-Saadany S., El-Demerdash T., Helmy A., Mayah W.W., El-Sayed H.B., Hassanien M., Elmashad N., Fouad M.A., Basha E.A. Diagnostic value of Glypican-3 for hepatocellular carcinomas. Asian Pac. J. Cancer Prev. APJCP. 2018; 19 (3): 811–817. https://doi.org/10.22034/APJCP.2018.19.3.811.

57. Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) https://clinicaltrials.gov/ct2/show/NCT02905188 (дата обращения: 06.05.2020).

58. Allan B.J., Wang B., Davis J.S., Parikh P.P., Perez E.A., Neville H.L., Sola J.E. A review of 218 pediatric cases of hepatocellular carcinoma. J. Pediatr. Surg. 2014; 49 (1): 166–171; discussion 171. https://doi.org/10.1016/j.jpedsurg.2013.09.050.

59. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334 (11): 693–699. https://doi.org/10.1056/NEJM199603143341104.

60. Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg. Nutr. 2016; 5 (6): 498–502. https://doi.org/10.21037/hbsn.2016.12.09.

61. De Ville G.J., Meyers R.L., Tiao G.M., Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. Lancet Gastroenterol. Hepatol. 2017; 2 (6): 456–462. https://doi.org/10.1016/s2468-1253(17)30084-5.

62. Squires R.H., Ng V., Romero R., Ekong U., Hardikar W., Emre S., Mazariegos G.V. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology. Hepatology. 2014; 60 (1): 362–398. https://doi.org/10.1002/hep.27191.

63. Malek M.M., Shah S.R., Atri P., Paredes J.L., DiCicco L.A., Sindhi R., Soltys K.A., Mazariegos G.V., Kane T.D. Review of outcomes of primary liver cancers in children: our institutional experience with resection and transplantation. Surgery. 2010; 148 (4): 778–782. https://doi.org/10.1016/j.surg.2010.07.021.

64. Beaunoyer M., Vanatta J.M., Ogihara M., Strichartz D., Dahl G., Berquist W.E., Castillo R.O., Cox K.L., Esquivel C.O. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr. Transplant. 2007; 11 (6): 655–660. https://doi.org/10.1111/j.1399-3046.2007.00751.x.

65. Ismail H., Broniszczak D., Kaliciński P. Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients? Pediatr. Transplant. 2009; 13 (6): 682–692. https://doi.org/10.1111/j.1399-3046.2009.01062.x.

66. Kosola S., Lauronen J., Sairanen H. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr. Transplant. 2010; 14 (5): 646–650. https://doi.org/10.1111/j.1399-3046.2010.01312.x.

67. McAteer J.P., Goldin A.B., Healey P.J., Gow K.W. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr. Transplant. 2013; 17 (8): 744–750. https://doi.org/10.1111/petr.12144.


Для цитирования:


Ахаладзе Д.Г., Рабаев Г.С. Гепатоцеллюлярный рак у детей - основные отличия от взрослых пациентов. Анналы хирургической гепатологии. 2020;25(4):85-94. https://doi.org/10.16931/1995-5464.2020485-94

For citation:


Akhaladze D.G., Rabaev G.S. Pediatric hepatocellular carcinoma - the main differences from adult patients. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2020;25(4):85-94. (In Russ.) https://doi.org/10.16931/1995-5464.2020485-94

Просмотров: 219


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5464 (Print)
ISSN 2408-9524 (Online)